Three-month treatment with pioglitazone reduces circulating C1q-binding adiponectin complex to total-adiponectin ratio, without changes in body mass index, in people with type 2 diabetes.

Abstract

We measured circulating C1q-binding adiponectin (C1q-APN) levels before and after 3-month treatment with pioglitazone in people with type 2 diabetes. The results indicate 3-month treatment with pioglitazone reduces circulating levels of C1q-APN/total-adiponectin ratio without changes in body mass index.

• Authors: Hideaki Nakatsuji, Ken Kishida, Hironori Kobayashi, Tohru Funahashi, Iichiro Shimomura, Senri Study II Group
• Journal: Diabetes research and clinical practice (Diabetes Res Clin Pract) Vol. 99 Issue 1 Pg. e14-7 (Jan 2013) ISSN: 1872-8227 [Electronic] Ireland
• PMID: 23142017 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Chemical References

• ADIPOQ protein, human
• Adiponectin
• Anti-Inflammatory Agents, Non-Steroidal
• Hypoglycemic Agents
• PPAR gamma
• Thiazolidinediones
• Complement C1q
• Pioglitazone

Topics

• Adiponectin (blood, metabolism)
• Aged
• Anti-Inflammatory Agents, Non-Steroidal (administration & dosage, therapeutic use)
• Body Mass Index
• Complement C1q (analysis, metabolism)
• Diabetes Mellitus, Type 2 (blood, drug therapy, immunology)
• Down-Regulation (drug effects)
• Drug Monitoring
• Enzyme-Linked Immunosorbent Assay
• Female
• Humans
• Hypoglycemic Agents (administration & dosage, therapeutic use)
• Japan
• Male
• Middle Aged
• Molecular Weight
• PPAR gamma (agonists)
• Pioglitazone
• Thiazolidinediones (administration & dosage, therapeutic use)
• Time Factors
• Up-Regulation (drug effects)